GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cizzle Biotechnology Holdings CIZ.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

1.15p

0.00%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

At a glance

Figures in GBP, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−£691,000

FY2016FY2025

Free cash flow

−£498,000

FY2016FY2025

Shareholders' equity

−£340,000

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue———————£74,000£4.5m£5.3m
Research and development£234,000£213£214£280,000£161,000—————
Operating income−£753,000−£878,000−£976,000−£963,000£2.3m−£229,000−£21,710−£1.7m−£2.0m−£1.4m
Net income−£691,000−£2,166−£1,717−£912,000−£3.9m−£306,000−£21,706−£2.1m−£118−£159
Diluted earnings per share-0.00-0.00-0.00-0.00-0.02-0.01-0.00-0.97-0.00-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets£245,000£492,000£1.7m£2.8m£1.2m£90,000£16,477£96,000£3.1m£4.5m
Cash and short-term investments£116,000£387,000£1.6m£478,000£875,000£84,000£12,817£4,000£44,000£225,000
Total liabilities£585,000£410,000£186,000£145,000£218,000£58,000£9,846£331,000£2.3m£2.3m
Debt—————£10,000——£833,000£831,000
Shareholders' equity−£340,000£82,000£1.5m£2.6m£937,000£32,000£6,631−£235,000£741,000£2.2m
Shares outstanding396m396m364m308m253m25m25m2m1m1m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−£496,000−£358,000−£639,000−£872,000−£1.0m−£294,000−£7,072−£513,000−£190,000£186,000
Capital spending−£2,000———−£200,000——−£176,000−£467,000−£907,000
Free cash flow−£498,000−£358,000−£639,000−£872,000−£1.2m−£294,000−£7,072−£689,000−£657,000−£721,000

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Mar 2024Dec 2023Sept 2023
Operating income−£354,000−£371,000−£408,000−£877,701−£419,000−£150−£519,000−£317
Net income−£329,000−£323,000−£368−£755−£1,411−£706−£1,286−£643
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets£191,000£245,000£257,000£492,000£923,000£923,000£1.7m£1.7m
Cash and short-term investments£81,000£116,000£182,000£387,000£816,000£816,000£1.6m£1.6m
Debt——£150,000—————
Shareholders' equity−£337,000−£340,000−£276,000£82,000£794,000£794,000£1.5m£1.5m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-7.9%26.9%-12.9%
Net income-8.8%17.7%-13.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-8.9-2836.6-4132.2-4.9-1.9

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.